Bamco Inc. NY Makes New $45.09 Million Investment in Neogen Corporation $NEOG

Bamco Inc. NY bought a new stake in shares of Neogen Corporation (NASDAQ:NEOG - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 5,015,968 shares of the company's stock, valued at approximately $45,094,000. Bamco Inc. NY owned 2.30% of Neogen as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of NEOG. UMB Bank n.a. grew its position in Neogen by 238.2% during the fourth quarter. UMB Bank n.a. now owns 6,422 shares of the company's stock worth $45,000 after buying an additional 4,523 shares in the last quarter. Hantz Financial Services Inc. boosted its position in Neogen by 816.9% in the fourth quarter. Hantz Financial Services Inc. now owns 7,592 shares of the company's stock valued at $53,000 after buying an additional 6,764 shares in the last quarter. Cresset Asset Management LLC acquired a new position in Neogen in the second quarter valued at about $53,000. Evergreen Capital Management LLC bought a new stake in Neogen during the second quarter worth about $56,000. Finally, Northwestern Mutual Wealth Management Co. grew its stake in Neogen by 3,158.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 8,309 shares of the company's stock worth $58,000 after buying an additional 8,054 shares during the last quarter. 96.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently commented on NEOG. Weiss Ratings upgraded Neogen from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, August 7th. Piper Sandler upgraded Neogen from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $13.00 to $14.00 in a research report on Wednesday. Finally, Wall Street Zen raised Neogen from a "hold" rating to a "buy" rating in a research note on Saturday, May 9th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $12.00.

More Neogen News

Here are the key news stories impacting Neogen this week:

• Positive Sentiment: Piper Sandler upgraded Neogen on new management. The brokerage’s improved view suggests investors may expect management changes to improve execution, profitability, or growth. Neogen upgraded at Piper Sandler on new management
• Positive Sentiment: Zacks Research raised several future EPS forecasts. Estimates increased for the second and third quarters of fiscal 2027, the fourth quarter of fiscal 2027, and the third and fourth quarters of fiscal 2028. The full-year fiscal 2028 forecast also rose to $0.29 per share from $0.28, indicating modestly better expected earnings momentum. The current-year consensus remains $0.25 per share.
• Positive Sentiment: Neogen is receiving attention from value-oriented investors. A Zacks comparison of Neogen and Perrigo highlights investor interest in the medical-products sector and could increase visibility for NEOG among investors seeking a relatively attractive valuation. PRGO or NEOG: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Analysts’ price target is near the recent trading level. The reported consensus target of $11.67 suggests limited near-term upside based on that estimate, although targets can change following the Piper Sandler upgrade. Analysts Set Neogen Corporation PT at $11.67
• Neutral Sentiment: Short-interest data provides no meaningful signal. The report lists zero shares sold short and a zero-day short ratio, figures that appear anomalous and do not indicate either significant short-covering potential or notable bearish positioning.
• Negative Sentiment: Not all forecasts improved. Zacks lowered its fiscal first-quarter 2028 EPS estimate to $0.05 from $0.06, signaling that the earnings outlook remains uneven despite the broader upward revisions.

Neogen Stock Up 0.5%

NASDAQ:NEOG opened at $11.70 on Thursday. The firm has a market capitalization of $2.55 billion, a P/E ratio of -390.00, a P/E/G ratio of 4.59 and a beta of 1.77. The stock's fifty day simple moving average is $10.37 and its 200-day simple moving average is $9.85. The company has a quick ratio of 2.91, a current ratio of 3.82 and a debt-to-equity ratio of 0.38. Neogen Corporation has a 12-month low of $4.90 and a 12-month high of $12.85.

Neogen (NASDAQ:NEOG - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.06 by $0.03. Neogen had a negative net margin of 0.91% and a positive return on equity of 2.78%. The firm had revenue of $225.30 million during the quarter, compared to the consensus estimate of $212.35 million. During the same quarter in the prior year, the firm earned ($2.82) earnings per share. The business's quarterly revenue was down .1% on a year-over-year basis. Equities research analysts expect that Neogen Corporation will post 0.25 earnings per share for the current year.

About Neogen

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen's product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.

Want to see what other hedge funds are holding NEOG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neogen Corporation (NASDAQ:NEOG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source